Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee

PHASE3CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

February 20, 2017

Primary Completion Date

July 19, 2018

Study Completion Date

July 19, 2018

Conditions
Osteoarthritis of the Knee
Interventions
DRUG

FX006 32 mg

Single intra-articular injection

Trial Locations (17)

14609

Rochester Clinical Research, Rochester

16635

Altoona Center for Clinical Research, Duncansville

27701

Duke University, Durham

29425

Medical University of South Carolina, Charleston

29464

Coastal Carolina Research Center, Mt. Pleasant

32561

The Andrews Institute, Gulf Breeze

37761

Tampa Bay Medical Research, Clearwater

37938

PMG Research of Knoxville, Knoxville

70121

Ochsner Sports Medicine Institute, New Orleans

85712

Tucson Orthopedic, Tucson

90048

Cedars-Sinai Medical Center, Los Angeles

90509

Harbor-UCLA Medical Center, Torrance

91303

Hope Clinical Research, Canoga Park

92103

Artemis Institute for Clinical Research, San Diego

92801

Dream Team Clinical Research, Anaheim

02467

Brigham and Women's Hospital, Chestnut Hill

02026

New England Baptist Hospital, Dedham

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY

NCT03046446 - Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee | Biotech Hunter | Biotech Hunter